The deal marks Gilead's latest big-ticket move into oncology this year, with Immunomedics' Trodelvy anticipated to reach $4 billion in peak sales. However, at least one analyst suggested Gilead may have overpaid.
The KEYNOTE-119 study failed to show a survival benefit in TNBC patients. The news comes two months after the FDA gave accelerated approval to a rival, Roche's Tecentriq.
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.